NxStage® System One

NxStage System One is a simple, flexible, and portable system providing the growing number of people with end-stage renal disease better options for haemodialysis treatments.

NxStage System One was designed with patients in mind to provide simplicity, flexibility, and portability without compromising safety. System One was designed to overcome the challenges posed by traditional equipment and is the first truly portable haemodialysis system for home and clinic use.

Improving Quality of Life

Compared to conventional 3 days per week dialysis, more frequent dialysis, during the day (HHD) or overnight (NHHD), may provide significant clinical and quality of life benefits including:

  • More energy1-4
  • Improved appetite5
  • Quicker time to recovery6
  • Lower risk of death7,8
  • Improved quality of life

Making Dialysis Accessible

  • The simple interface is easy to learn and use
  • Simple plumbing connections and standard electrical plug minimise the impact in patients’ homes
  • Easy-to-use drop-in cartridge allows for easy wipe-down disinfection after each use
  • Our 24/7 dedicated technical support team offers your patients peace of mind while dialysing, no matter when or where
  • Portability gives your patients freedom to travel or dialyse within the comfort of their own home
Risks and Responsibilities

Despite the health benefits that home and more frequent hemodialysis may provide to those with chronic kidney disease, these forms of therapy are not for everyone. Home hemodialysis with the NxStage System One requires a patient and partner who are committed to being trained on and following the guidelines for proper system operation.

The reported benefits of home hemodialysis may not be experienced by all patients.

The NxStage System One is a prescription device and, like all medical devices, involves some risks. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. When vascular access is exposed to more frequent use, infection of the site, and other access related complications may also be potential risks. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream, and blood loss due to clotting or accidental disconnection of the blood tubing set.

Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.

Certain risks associated with hemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping. These risks include, but are not limited to, blood access disconnects and blood loss during sleep, blood clotting due to slower blood flow or increased treatment time or both, and delayed response to alarms when waking from sleep.

Patients should consult their doctor to understand the risks and responsibilities of performing these therapies using the NxStage System.

  1. Finkelstein F, Gehr T, Kraus M, et al. Daily haemodialysis (DHD) improves quality of life (QofL): Interim results from the FREEDOM study. Abstract presented as poster at Annual Dialysis Conference, 2011.
  2. Heidenheim PA, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian haemodialysis. Am J Kidney Dis. 2003;42(S1)(S1):S36-S41.
  3. Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily haemodialysis. Am J Kidney Dis. 2003;42(5):1020-1035.
  4. Goldfarb-Rumyantzev AS, Leypoldt JK, Nelson N, Kutner NG, Cheung AK. A crossover study of short daily haemodialysis. Nephrol Dial Transplant. 2006;21:166-175.
  5. Spanner E, Suri R, Heidenheim AP, Lindsay RM. The impact of quotidian haemodialysis on nutrition. Am J Kidney Dis. 2003;42(1 suppl):30-35
  6. Jaber BL, Lee Y, Collins AJ, et al. Effect of daily haemodialysis on depressive symptoms and postdialysis recovery time: interim report from the FREEDOM (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study. Am J Kidney Dis. 2010;56(3):531-539.
  7. Pauly RP, Gill JS, Rose CL, Asad RA, Chery A, Pierratos A, Chan CT. Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients. Nephrol Dial Transplant. 2009;24:2915-2919.
  8. Weinhandl ED, Lie J, Gilbertson DT, Arneson TJ, Collins AJ. Survival in daily home haemodialysis and matched thrice-weekly in-center haemodialysis patients. J Am Soc Nephrol. 2012;23(5):895-904.
APM2171-ENG Rev. A

Fresenius Medical Care has successfully completed its merger with NxStage Medical, Inc.

More Info